Brief: Solid Biosciences Receives Rare Pediatric Disease Designation From FDA For Gene Therapy Candidate SGT-003

Solid Biosciences

01/04/2024 13:18

April 1 (Reuters) - Solid Biosciences Inc  SLDB.O :
    * SOLID BIOSCIENCES RECEIVES RARE PEDIATRIC DISEASE
DESIGNATION
FROM THE FDA FOR DUCHENNE MUSCULAR DYSTROPHY GENE THERAPY
CANDIDATE SGT-003
    * SOLID BIOSCIENCES INC - SITE INITIATIONS SCHEDULED FOR
APRIL;
PATIENT DOSING EXPECTED TO BEGIN IN Q2 2024
    * SOLID BIOSCIENCES INC - ANTICIPATE PROVIDING AN INITIAL
SAFETY
UPDATE FOR FIRST THREE TO FOUR PATIENTS ENROLLED IN INSPIRE
DUCHENNE TRIAL IN MID-2024

Source text for Eikon:  ID:nGNX28XF1n 
Further company coverage:  SLDB.O 

 ((Reuters.Briefs@thomsonreuters.com;))